Orakl Oncology SAS

Based in France, Orakl Oncology operates as a biotechnology firm specializing in AI-driven tools that enhance cancer drug development through innovative predictive technologies. Orakl Oncology SAS, founded in 2022, is a biotechnology firm focused on improving cancer drug development using AI-native predictive tools. The company has successfully secured EUR 11. 000 mn in Seed funding led by Singular, with participation from Bpifrance.

This funding round was completed on December 3, 2024. Orakl was established by a team of experienced professionals in the oncology sector, although specific details on the founder's previous ventures are not disclosed. The firm is headquartered in France and has engaged in two deals since its inception. Orakl Oncology delivers an innovative suite of AI-native predictive tools designed to enhance cancer drug development.

Central to their offerings is a platform that integrates patient-derived biological data, advanced artificial intelligence, and real-world data to identify new drug targets and predict patient responses to therapies. By employing a closed-loop system that incorporates proprietary lab-generated multimodal data, Orakl transforms complex biological information into actionable insights, streamlining the drug discovery and development process. Their solutions are utilized primarily by leading pharmaceutical companies and academic research institutions, allowing them to de-risk clinical trials and expedite drug approvals. The company is focused on expanding its presence in international markets, partnering with healthcare providers across Europe and beyond to build and utilize a robust living avatar tumor collection that enhances the understanding of patient-derived heterogeneity.

Orakl Oncology generates revenue through partnerships with pharmaceutical companies and institutions, focusing on collaborative projects that leverage their predictive platform for drug development. These partnerships often involve establishing subscriptions for access to their AI-powered tools and datasets, facilitating a continuous engagement model that allows clients to utilize the platform for ongoing research and trial assessments. The company also engages in contractual agreements for specific projects, where clients pay for access to the comprehensive multimodal datasets that are crucial for informed decision-making in clinical trials. The structure of these transactions is primarily B2B, with pharmaceutical companies and research institutions as the key clientele.

Through these strategic partnerships, Orakl Oncology enhances its financial growth while contributing significantly to the efficiency of oncology drug development. In December 2024, Orakl Oncology SAS raised EUR 11. 000 mn in Seed funding to support its growth initiatives, particularly in building a dedicated business unit and launching new oncology drug development products. The company plans to expand its reach into new markets across Europe and beyond.

This funding will help facilitate the development of innovative products aimed at enhancing the drug discovery process, thereby improving clinical outcomes in oncology. Orakl's strategy includes engaging with healthcare providers to foster collaborations that leverage their predictive capabilities, ultimately aiming to enhance patient care through advanced drug therapies.